These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 27744129)

  • 1. Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME.
    Scheen AJ
    Diabetes Res Clin Pract; 2016 Nov; 121():204-214. PubMed ID: 27744129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME.
    Scheen AJ; Delanaye P
    Diabetes Metab; 2017 Apr; 43(2):99-109. PubMed ID: 28153377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics.
    Scheen AJ
    Diabetes Metab; 2016 Sep; 42(4):224-33. PubMed ID: 27291329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of EMPA-REG OUTCOME
    Naing S; Poliyedath A; Khandelwal S; Sigala T
    Postgrad Med; 2016 Nov; 128(8):822-827. PubMed ID: 27701934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empagliflozin: A Review in Type 2 Diabetes.
    Frampton JE
    Drugs; 2018 Jul; 78(10):1037-1048. PubMed ID: 29946963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EMPA-REG OUTCOME: The Endocrinologist's Point of View.
    Perreault L
    Am J Med; 2017 Jun; 130(6S):S51-S56. PubMed ID: 28526185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
    Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
    Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Focus on empagliflozin : post hoc analyses of the cardiovascular outcome trial EMPA-REG OUTCOME].
    Scheen AJ
    Rev Med Liege; 2019 Apr; 74(4):185-191. PubMed ID: 30997967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Which is the main molecular target responsible for the cardiovascular benefits in the EMPA-REG OUTCOME trial? A journey through the kidney, the heart and other interesting places.
    Luconi M; Raimondi L; Di Franco A; Mannucci E
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1071-1078. PubMed ID: 27776917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EMPA-REG OUTCOME: The Endocrinologist's Point of View.
    Perreault L
    Am J Cardiol; 2017 Jul; 120(1S):S48-S52. PubMed ID: 28606344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.
    Trujillo JM; Nuffer WA
    Pharmacotherapy; 2017 Apr; 37(4):481-491. PubMed ID: 28102030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Novel therapeutic options in patients with type 2 diabetes and high cardiovascular risk].
    Laubner K; Seufert J
    Dtsch Med Wochenschr; 2016 Jun; 141(11):757-60. PubMed ID: 27176455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies.
    Ghosh RK; Bandyopadhyay D; Hajra A; Biswas M; Gupta A
    Int J Cardiol; 2016 Jun; 212():29-36. PubMed ID: 27017118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms linking empagliflozin to cardiovascular and renal protection.
    Perrone-Filardi P; Avogaro A; Bonora E; Colivicchi F; Fioretto P; Maggioni AP; Sesti G; Ferrannini E
    Int J Cardiol; 2017 Aug; 241():450-456. PubMed ID: 28395981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [EMPA-REG OUTCOME: Empagliflozin reduces mortality in patients with type 2 diabetes at high cardiovascular risk].
    Scheen AJ
    Rev Med Liege; 2015 Nov; 70(11):583-9. PubMed ID: 26738271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
    Wu JH; Foote C; Blomster J; Toyama T; Perkovic V; Sundström J; Neal B
    Lancet Diabetes Endocrinol; 2016 May; 4(5):411-9. PubMed ID: 27009625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EMPA-REG OUTCOME: The Nephrologist's Point of View.
    Wanner C
    Am J Med; 2017 Jun; 130(6S):S63-S72. PubMed ID: 28526179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal and Cardiovascular Effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial.
    Mordi NA; Mordi IR; Singh JS; Baig F; Choy AM; McCrimmon RJ; Struthers AD; Lang CC
    BMJ Open; 2017 Oct; 7(10):e018097. PubMed ID: 29042392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms.
    Staels B
    Am J Med; 2017 Jun; 130(6S):S30-S39. PubMed ID: 28526184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.